PDSB - PDS Biotechnology added to Russell Microcap Index

On the conclusion of the 2021 Russell indexes annual reconstitution, clinical-stage immunotherapy company PDS Biotechnology (PDSB) joined the Russell Microcap Index. Frank Bedu-Addo, President and CEO of PDS Biotech, commented, "Inclusion in the Russell Microcap Index underscores the progress we are making towards potentially improving the effectiveness of cancer therapy and increasing shareholder value by progressing our three (3) Phase 2 clinical programs for our lead HPV-cancer immunotherapy PDS0101. We look forward to continuing to progress the clinical development of PDS0101 while also moving additional oncology pipeline products into human testing within the next year." Shares +1.355% premarketPress Release

For further details see:

PDS Biotechnology added to Russell Microcap Index